Laboratory Tests for Lymphoma Workup
The essential laboratory workup for lymphoma includes complete blood count with differential, comprehensive metabolic panel (renal and liver function), LDH, β2-microglobulin, protein electrophoresis, serum and urine immunofixation, and viral serology (HBV, HCV, HIV), with bone marrow aspirate and biopsy required for most subtypes. 1, 2, 3
Core Laboratory Studies (Mandatory for All Lymphomas)
Hematologic Assessment
- Complete blood count with differential and platelet count - identifies cytopenias, circulating lymphoma cells
- Peripheral blood flow cytometry - mandatory in nodal marginal zone lymphoma (NMZL) and splenic marginal zone lymphoma (SMZL); optional in extranodal marginal zone lymphoma (EMZL) 1
Biochemistry Panel
- Comprehensive metabolic panel including:
Tumor Burden and Prognostic Markers
- Lactate dehydrogenase (LDH) - elevated in high tumor burden, prognostic significance 1, 2, 3
- β2-microglobulin (B2M) - prognostic marker, incorporated into FLIPI-2 scoring for follicular lymphoma 2, 3
- Uric acid - assess tumor lysis risk 2
Protein Studies
- Serum protein electrophoresis - detects monoclonal proteins 1
- Serum and urine immunofixation - characterizes monoclonal components 1
- Quantitative immunoglobulins - baseline assessment 3
Infectious Disease Screening (Critical)
Hepatitis B virus testing is mandatory before anti-CD20 therapy due to reactivation risk 2, 4, 3:
- HBsAg (hepatitis B surface antigen)
- HBcAb (hepatitis B core antibody)
Additional viral serology:
- Hepatitis C virus (HCV) - mandatory screening; if positive, obtain HCV-RNA PCR and genotyping (particularly important in splenic and extranodal marginal zone lymphomas) 1
- HIV serology 1, 2, 4
Subtype-Specific Laboratory Tests
For Marginal Zone Lymphomas:
For Follicular Lymphoma:
- Immunoglobulin levels for FLIPI scoring 3
Bone Marrow Evaluation
When Mandatory
- Nodal marginal zone lymphoma (NMZL) - bone marrow aspirate with morphology/flow cytometry plus biopsy 1
- Splenic marginal zone lymphoma (SMZL) - bone marrow aspirate with morphology/flow cytometry plus biopsy 1
- Follicular lymphoma - bone marrow aspirate and biopsy (minimum 20 mm length) 2, 3
- Mantle cell lymphoma - bone marrow aspirate and biopsy 5
When Highly Recommended
- Extranodal marginal zone lymphoma (EMZL) - particularly in non-gastric lymphoma and when only local treatment is planned 1
Exception
Bone marrow biopsy may be omitted in Hodgkin lymphoma and DLBCL if PET-CT is performed and shows no bone involvement 6. However, for DLBCL, bone marrow biopsy is still needed if PET is negative and identifying discordant histology would change management 6.
Common Pitfalls to Avoid
Forgetting hepatitis B screening - This is non-negotiable before rituximab or chemotherapy; reactivation can be fatal 2, 4
Inadequate bone marrow specimen - Biopsy should be at least 20 mm in length for adequate assessment 3
Omitting flow cytometry in marginal zone lymphomas - Peripheral blood flow cytometry is mandatory in NMZL and SMZL for diagnosis 1
Not testing HCV in appropriate contexts - Essential in splenic marginal zone lymphoma where HCV may be causative 1
Incomplete protein studies - Both serum and urine immunofixation are required, not just serum 1
Algorithmic Approach by Lymphoma Subtype
For Marginal Zone Lymphomas:
- Start with complete laboratory panel above
- Add mandatory peripheral blood flow cytometry for NMZL/SMZL
- Obtain bone marrow (mandatory for NMZL/SMZL, highly recommended for EMZL)
- Check HCV serology; if positive, add HCV-RNA PCR, genotyping, cryoglobulins 1
For Follicular Lymphoma:
- Complete laboratory panel
- Bone marrow aspirate and biopsy (≥20 mm)
- Calculate FLIPI score using: age, stage, hemoglobin, LDH, number of nodal areas 2, 3
For Aggressive Lymphomas (DLBCL, Mantle Cell):
- Complete laboratory panel with emphasis on LDH and B2M
- Consider bone marrow if PET-CT not performed or shows equivocal findings 6
- Ki-67 proliferation index mandatory for mantle cell lymphoma 5
The strength of these recommendations comes from consistent ESMO guidelines across multiple lymphoma subtypes 1, 2, 1, 3, 5, representing the highest quality evidence available for lymphoma staging workup.